VYNE Therapeutics Inc. entered into a Securities Purchase Agreement for a private placement transaction, expecting to receive gross proceeds of $88.2 million; terminated a purchase agreement with Lincoln Park Capital Fund; expects to report $15.5 million in cash and cash equivalents as of September 30, 2023; announced the date of its 2023 Annual Meeting of Stockholders; issued press releases on positive trial data and updated corporate presentation; intends to increase the size of the Board and appoint a designee of Access Biotechnology, Inc.